SynthesisEye (London, England)2023
Myopia prevention and control in children: a systematic review and network meta-analysis.
Synthesis in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Duration-Dependent Efficacy and Clinical Safety of Repeated Low-Level Red-Light Therapy for Paediatric Myopia: A Systematic Review and Meta-Analysis.Clinical & experimental ophthalmology · 2026Pooled it
- Efficacy and safety of low-concentration atropine combined with orthokeratology for children with myopia: a systematic review and meta-analysis of randomized controlled trials.BMC ophthalmology · 2026Pooled it
- Efficacy of interventions for myopia control in children: A systematic review with network meta-analyses.Acta ophthalmologica · 2025Pooled it
- Efficacy comparison of atropine, orthokeratology and repeated low-level red-light therapy for myopia control in children: a systematic review and network meta-analysis.The British journal of ophthalmology · 2025Pooled it
- Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.European journal of ophthalmology · 2024Guideline
- Twice versus once daily application of 0.01% atropine for myopia control in children: a randomised controlled trial.Eye (London, England) · 2025Trial
- Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes.Ophthalmology and therapy · 2026Review
- Binocular Non-Cycloplegic Ocular Parameters for Modeling Cycloplegic SER in Children.Translational vision science & technology · 2026Article
- Neuro-ophthalmic review on pediatric myopia: Advancing from refraction to a brain-centric model of axial growth.World journal of clinical pediatrics · 2026Review
- Age Modifies the Comparative Effectiveness of DIMS Versus HAL Spectacle Lenses for Myopia Control: A Real-World Study.Translational vision science & technology · 2026Article
- Effectiveness of Low-Dose Atropine Combined With Bright Light Therapy for Controlling Myopic Eye Growth in Schoolchildren: Study Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Myopia Management Consensus Statement in South Korean Children 2025 by the Korean Myopia Society for the Korean Association for Pediatric Ophthalmology and Strabismus.Korean journal of ophthalmology : KJO · 2026Review
- Antimicrobial nanocoatings and films for contact lenses: progress and promise.Nanomedicine (London, England) · 2026Review
- Association Between Pupil Area and the Efficacy of Peripheral Defocus Spectacle Lenses in Myopia Control.Translational vision science & technology · 2026Article
- Positive/negative binocular fusional C-optotypes and 2D planar C-optotypes on transient accommodation and stability in adult eyes: implications for myopia prevention and control.International journal of ophthalmology · 2026Article
- Childhood myopia in the modern environment: modifiable risk factors and evidence-based prevention.International journal of ophthalmology · 2026Review
- Interocular Posterior Retinal Curvature Asymmetry and Its Relationship With Myopic Differences in Anisometropic Children.Translational vision science & technology · 2025Article
- Age, gender and regional/ethnic variations in emmetropic axial growth rate.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Childhood Myopia Part II: Treatment Mechanisms, Emerging Options, and Considerations.Investigative ophthalmology & visual science · 2025Review
- Does 0.01% atropine have a place as a myopia control therapy?Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo analyse and compare the efficacy of different interventions for myopia prevention and control in children.
methodsWe searched CNKI, VIP, Wan-Fang, CBM, Chinese Clinical Registry, PubMed, The Cochrane Library, Web of Science, Embase and ClinicalTrials.gov from inception to July 2022. We selected randomized controlled trials (RCTs) that included interventions to slow myopia progression in children. The main outcomes included mean annual change in axial length (AL) (millimetres/year) and in refraction (R) (dioptres/year).
resultsA total of 80 RCTs (27103 eyes) were included. In comparison with control, orthokeratology (AL, -0.36 [-0.53, -0.20], P < 0.05; R, 0.56 [0.34, 0.77], P < 0.05), 1%Atropine (AL, -0.39 [-0.65, -0.13], P < 0.05; R, 0.54 [0.31, 0.77], P < 0.05), 0.01%Atropine + orthokeratology (AL, -0.47 [-0.80, -0.14], P < 0.05; R, 0.81 [0.43, 1.20], P < 0.05) could significantly slow the progression of myopia; in addition, progressive multi-focal spectacle lenses (PMSL) (0.42, [0.06, 0.79], P < 0.05), bifocal soft contact lenses (0.40, [0.03, 0.77], P < 0.05), 0.5%Atropine (0.67 [0.25, 1.10], P < 0.05), 0.1%Atropine (0.42 [0.15, 0.71], P < 0.05), 0.05%Atropine (0.57 [0.28, 0.86], P < 0.05), 0.01%Atropine (0.33 [0.15, 0.52], P < 0.05), 1%Atropine + bifocal spectacle lenses (BSL) (1.30 [0.54, 2.00], P < 0.05), 1%Atropine + PMSL (0.66 [0.23, 1.10], P < 0.05), 0.01%Atropine + single vision spectacle lenses (SVSL) (0.70 [0.23, 1.10], P < 0.05), 0.01%Atropine + orthokeratology (0.81 [0.43, 1.20], P < 0.05), BSL + Massage (0.85 [0.22, 1.50], P < 0.05), SVSL + Red light (0.59 [0.06, 0.79], P < 0.05) showed significant slowing effect on the increase in R.
conclusionsThis network meta-analysis suggests that the combined measures were most effective in AL and R, followed by Atropine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.